Decreased specific CD8+ T cell cross-reactivity of antigen recognition following vaccination with Melan-A peptide
- PMID: 16761313
- DOI: 10.1002/eji.200535805
Decreased specific CD8+ T cell cross-reactivity of antigen recognition following vaccination with Melan-A peptide
Abstract
The aim of T cell vaccines is the expansion of antigen-specific T cells able to confer immune protection against pathogens or tumors. Although increase in absolute cell numbers, effector functions and TCR repertoire of vaccine-induced T cells are often evaluated, their reactivity for the cognate antigen versus their cross-reactive potential is rarely considered. In fact, little information is available regarding the influence of vaccines on T cell fine specificity of antigen recognition despite the impact that this feature may have in protective immunity. To shed light on the cross-reactive potential of vaccine-induced cells, we analyzed the reactivity of CD8(+) T cells following vaccination of HLA-A2(+) melanoma patients with Melan-A peptide, incomplete Freund's adjuvant and CpG-oligodeoxynucleotide adjuvant, which was shown to induce strong expansion of Melan-A-reactive CD8(+) T cells in vivo. A collection of predicted Melan-A cross-reactive peptides, identified from a combinatorial peptide library, was used to probe functional antigen recognition of PBMC ex vivo and Melan-A-reactive CD8(+) T cell clones. While Melan-A-reactive CD8(+) T cells prior to vaccination are usually constituted of widely cross-reactive naive cells, we show that peptide vaccination resulted in expansion of memory T cells displaying a reactivity predominantly restricted to the antigen of interest. Importantly, these cells are tumor-reactive.
Similar articles
-
Simultaneous CD8+ T cell responses to multiple tumor antigen epitopes in a multipeptide melanoma vaccine.Cancer Immun. 2003 Oct 28;3:15. Cancer Immun. 2003. PMID: 14580186
-
Dacarbazine treatment before peptide vaccination enlarges T-cell repertoire diversity of melan-a-specific, tumor-reactive CTL in melanoma patients.Cancer Res. 2010 Sep 15;70(18):7084-92. doi: 10.1158/0008-5472.CAN-10-1326. Epub 2010 Sep 7. Cancer Res. 2010. PMID: 20823160
-
Suboptimal activation of CD8(+) T cells by melanoma-derived altered peptide ligands: role of Melan-A/MART-1 optimized analogues.Cancer Res. 2003 Apr 1;63(7):1560-7. Cancer Res. 2003. PMID: 12670905
-
Melanoma antigens recognised by CD8+ and CD4+ T cells.Forum (Genova). 2000 Jul-Sep;10(3):256-70. Forum (Genova). 2000. PMID: 11007933 Review.
-
Immunity to melanoma antigens: from self-tolerance to immunotherapy.Adv Immunol. 2006;90:243-95. doi: 10.1016/S0065-2776(06)90007-8. Adv Immunol. 2006. PMID: 16730266 Review.
Cited by
-
Nano-particle vaccination combined with TLR-7 and -9 ligands triggers memory and effector CD8⁺ T-cell responses in melanoma patients.Eur J Immunol. 2012 Nov;42(11):3049-61. doi: 10.1002/eji.201142361. Epub 2012 Aug 28. Eur J Immunol. 2012. PMID: 22806397 Free PMC article. Clinical Trial.
-
Paclitaxel reduces regulatory T cell numbers and inhibitory function and enhances the anti-tumor effects of the TLR9 agonist PF-3512676 in the mouse.Cancer Immunol Immunother. 2009 Apr;58(4):615-28. doi: 10.1007/s00262-008-0586-2. Epub 2008 Sep 19. Cancer Immunol Immunother. 2009. PMID: 18802696 Free PMC article.
-
Murine CD8 T-cell functional avidity is stable in vivo but not in vitro: Independence from homologous prime/boost time interval and antigen density.Eur J Immunol. 2020 Apr;50(4):505-514. doi: 10.1002/eji.201948355. Epub 2019 Dec 10. Eur J Immunol. 2020. PMID: 31785153 Free PMC article.
-
The good and the bad of T cell cross-reactivity: challenges and opportunities for novel therapeutics in autoimmunity and cancer.Front Immunol. 2023 Jun 19;14:1212546. doi: 10.3389/fimmu.2023.1212546. eCollection 2023. Front Immunol. 2023. PMID: 37409132 Free PMC article. Review.
-
Expression of inhibitory receptors on intratumoral T cells modulates the activity of a T cell-bispecific antibody targeting folate receptor.Oncoimmunology. 2015 Jun 24;5(2):e1062969. doi: 10.1080/2162402X.2015.1062969. eCollection 2016 Feb. Oncoimmunology. 2015. PMID: 27057429 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials